SEARCH

SEARCH BY CITATION

References

  • 1
    Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32:673684.
  • 2
    Papatheodoridis GV, Davies S, Dhillon AP, Teixeira R, Goulis J, Davidson B, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001; 72:412418.
  • 3
    Papatheodoridis GV, Barton SG, Andrew D, Clewley G, Davies S, Dhillon AP, et al. Longitudinal variation in hepatitis C virus (HCV) viramenia and early course of HCV infection after liver transplantation for HCV cirrhosis: The role of different immunosuppressive regimens. Gut 1999; 45:427434.
  • 4
    Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5(suppl):S107S114.
  • 5
    Gane EJ, Naoumov NV, Qian KP, Mondelli MN, Maertens G, Portmann BC, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110:167177.
  • 6
    Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21:3034.
  • 7
    Sreekumar R, Gonzales-Koch A, Maor-Kendler Y, Batts Moreno-Luna L, Poterucha J, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32:11251130.
  • 8
    Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92:14531457.
  • 9
    Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: A report of the United States FK506 Study Group. Transplantation 1998; 66:493499.
  • 10
    Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: Results of a prospective randomized trial. Liver Transpl 2001; 7:693697.
  • 11
    Kneteman NM. Steroid-free immunosuppression: Balancing efficacy and toxicity. Liver Transpl 2001; 7:698700.
  • 12
    Brillanti S, Vivarelli M, DeRuvo N, Aden AA, Camaggi V, D'Errico AD, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8:884888.
  • 13
    Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7:442450.
  • 14
    Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8:4046.
  • 15
    Fasola CG, Netto G, Christensen LL, Rakela J, Thomas M, Onaca N, et al. Lower incidences of early hepatitis C RNA levels and HCV recurrence post liver transplantation in patients induced with mycophenolate mofetil: A high-dose benefit [abstract]. Liver Transpl 2002; 8:C52A.
  • 16
    Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7:10641070.
  • 17
    Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, et al. Immunoprophylaxis with basilixamab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002; 8:123131.
  • 18
    Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8:132142.
  • 19
    Klupp J, Glanemann M, Bechstein WO, Platz KP, Langrehr JM, Keck H, et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Transplant Proc 1999; 31:11131114.
  • 20
    Firpi RJ, Nelson DR, Davis GL. Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl 2003; 9:5761.